Figure 2: CDK7 is a survival factor in PTCL. | Nature Communications

Figure 2: CDK7 is a survival factor in PTCL.

From: THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors

Figure 2

(a) CDK7 protein expression by immunohistochemistry in PTCL-NOS (n=18) and ALCL-ALKneg (n=17) cases. Representative microphotographs (upper pictures taken at 10 × , scale bar represents 100 μm and lower pictures at 40 × , scale bar represents 50 μm) are shown on the right. (b) Immunoblots of CTD phospho-Ser5 and phospho-Ser2 of RNA polymerase II (RP2) and total RNA polymerase II and CDK7 in PTCL cells treated with THZ1 for the indicated time points. (c) Proportion of dead cells in OCI-Ly12 and OCI-Ly13.2 cells treated with THZ1 500 nM for up to 72 h. (d) PARP1 and cleaved PARP1 in OCI-Ly12 and OCI-Ly13.2 cells treated with THZ1 500 nM for up to 24 h. (e) Caspases 7 and 3 activity in OCI-Ly12 and OCI-Ly13.2 cells treated with 500 nM of THZ1 for 12 and 24 h. Data is presented as fold-change in activity relative to vehicle as means with 95% CI for quintuplicates.

Back to article page